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ABSTRACT
Objectives: To study the consent process experienced
by participants who are enrolled in a molecular genetic
research study that aims to find new genetic mutations
responsible for an apparently inherited disorder.
Design: Semi-structured interviews and analysis/
description of main themes.
Participants: 78 members of 52 families who had been
recruited to a molecular genetic study.
Results: People were well informed about the goals, risks
and benefits of the genetic research study but could not
remember the consent process. They had mostly been
recruited to take part by trusted clinicians or their relatives
but had little memory of, or concern about signing
consent forms. Families appeared to regard the research
as a continuation of their, or their relatives’, clinical care.
Conclusions: Ethical review should be more flexible in its
attitude to consent forms and written information sheets
for some sorts of research. For rare genetic disease
studies where research has been discussed fully within
the clinical setting then the consent obtained at that time
could suffice rather than needing extra consent at a later
stage. However, clinician-researchers will need to ensure
that their duty of care extends for the duration of the
research and beyond.
The Declaration of Helsinki underpins the conduct
of research with human subjects.
1 It sets out
clearly the responsibilities of clinicians and
researchers to make sure that participants are not
subjected to undue risk of harm and it puts
informed consent as a fundamental requirement.
1
Ensuring that written records of consent are kept is
perceived as essential, for example, see the UK
Human Tissue Act
2 and UK Biobank
3. Some
researchers have raised concerns that insisting on
written consent may impede certain types of
research.
4
The UK National Research Ethics Service
5 has
clear guidelines for the design and content of
information sheets and accompanying consent
forms. The effect is to force researchers to follow
a consistent pattern despite variability in the type
of research being undertaken. This emphasis on the
documentation of consent may lead medical
researchers towards functional consent,
6 whereby
the responsibility to understand and acknowledge
any risks that may be incurred by participation in
research are transferred from researchers to parti-
cipants. This should enhance research participants’
autonomy (p308)
7 but how much they understand
the information sheets is hard to assess,
8 as is the
degree to which consent is based on the trust
relationships
9 which exists between the researcher
and participants or the context in which they are
being asked to participate (pp313–4).
7
Consent for genetic research is seen as particu-
larly sensitive because it may have consequences
for family members beyond the individual. Indeed,
the research may only be possible if multiple
members of the same family participate.
10 To
illustrate, once an individual is identified as
potentially carrying a genetic disorder, the proband
and immediate family will be asked to provide a
family tree identifying those people within the
family affected by the disorder. Selected family
members will be approached and asked for
information and sometimes blood samples for
genetic analysis. Issues relating to consent and
the possible coercion of relatives to take part need
to be handled sensitively by researchers. Similar
ethical dilemmas may arise in the clinical set-
ting.
10 11 In the UK, clear guidance for how consent
should be sought for genetic testing within clinical
genetics practice has recently been published which
takes account of all these difficulties.
12
In the clinical setting, if known disease-causing
genetic mutations are found, then individuals
within the family can be approached via their
relatives and offered the opportunity to see
whether or not they carry the mutation.
Appropriate genetic counselling before gene testing
will usually be offered. If no known genetic
mutation is identified in the routine genetics clinic,
then sometimes families are asked if they wish to
extend the investigation further. As further testing
is in pursuit of new knowledge and for the benefit
of a wider population of people than just the
family concerned, the process becomes a research
activity. There may not be definite outcomes or
any clear time scale, there may be uncertainties
about who ultimately is responsible for conveying
research findings to participants and from whom
they will get clinical care.
13 At this stage the rules
governing research, (eg, participant information
sheets and consent forms to be signed) take over,
even though in the eyes of the family the process
may seem unaltered from what has happened
before. Little is known about how these families
perceive research activity which appears as a
continuation of their clinical care.
A molecular genetics research project is under-
way that allows us to explore some of these issues.
The Genetics of Learning Disabilities (GOLD)
Study aims to find new mutations in new genes
that may be responsible for intellectual disability
(ID) in families with two or more affected males
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This international study has recruited several hundred families
where there are two or more males with ID.
14 The assessment of
ID varied depending on the referral route: some were totally
dependent for all their needs whilst others could live relatively
independently. The data upon which this paper is based derives
from a separate, but linked, study whose aim was to determine
the expectations and experiences of GOLD study participants
resident in the UK or Ireland—the Family study.
This paper focuses upon participants’ experiences of the
initial consent process for the GOLD study. It describes how
these families came to participate, their experiences of giving
consent and their knowledge, expectation and understanding of
the research to which they have consented. These data will be
used to comment on the operating framework for research on
rare genetic disorders in the UK. Although in the GOLD study
the genetic disorder under investigation is ID, this paper does
not attempt to discuss the issues relating to consent for
participating in research from those family members with
reduced or lack of mental capacity. This is a complicated issue
which raises a number of practical and ethical problems and will
be addressed fully in a separate paper.
METHODS
UK families were recruited to the GOLD study through their
local clinical geneticist and most were seen either by LR or JM in
their homes. Blood samples were taken from individuals for
molecular genetic analysis. Individuals included affected males,
their mothers, brothers, unaffected male cousins and their
mothers (aunts of affected males). Occasionally, family mem-
bers were not seen in person by the GOLD study team but were
given written information and asked to have blood samples
taken locally. All GOLD study participants were given an
information sheet which stated that: the study was research to
find the genetic causes of ID; blood samples would be needed;
results, if any, may take several years; who the researchers were;
and that there was no obligation to take part. They were asked
to sign consent forms and proxy consent was requested for
children and those who lacked capacity to do it themselves.
i
Members of 90 GOLD study kinships from the UK and
Ireland were invited to participate in the Family Study, which
was reviewed and given a favourable opinion by the London
multi-centre Research Ethics Committee. Initially, invitations
were sent to selected families who had already become part of
the GOLD study and where preliminary genetic research
analysis showed they were the most likely ones to have a gene
mutation found. Subsequently all families who joined the
GOLD study were visited by the research nurse and all of these
families were invited to participate in the Family Study.
For the Family Study, two methods of recruitment were
employed—a direct approach from the GOLD study team, and
secondary recruitment by one family member to another after
the initial contact. Those recruited directly were either sent our
information packages by the clinical geneticist or given them by
the research nurse (JM) when visiting a family. These packages
comprised an information sheet, consent form and pre-paid
reply envelope. Individuals were asked to return consent forms
to the researchers in Cambridge. Some returned the consent
form, but others indicated that they would prefer to be
contacted directly by telephone. Respondents were contacted
by HS or MP to arrange an interview. We could only access
relatives through the person we first interviewed. Prior to
interview most had signed consent forms and at interview
consent was reconfirmed.
All interviews were tape recorded and transcribed verbatim.
Organisation of the data for analysis was aided by the use of
ATLAS-ti.
15 A thematic analysis was undertaken in which
recurring themes, within and across interviews, were identi-
fied.
16 HS and MP crosschecked transcripts to verify emergent
themes. The interview followed a schedule with prompts and
was developed by MP and HS during a period of consultation
and pilot interviews with families affected by Fragile X
syndrome. The topics covered ranged from factual information
about their families, their experiences of having ID in family
members, and their experience, knowledge, expectations of and
understanding of the GOLD study. This paper focuses upon a
subset of the data which concentrated on participants’
experiences of becoming involved in the GOLD study and their
memory and understanding of the consent process.
RESULTS
Characteristics of the study participants in the family study
Members of 35 kinships (39% of 90 invited) took part in this
study. Overall, 114 individuals from 52 families (some kinships
comprised several families) agreed to participate. Eighty-four
individuals had either donated a blood sample to the GOLD
study or been part of the consent process for an affected person.
The remaining 30 relatives had not been required to give a blood
sample for the GOLD study and so the data from their
interviews is not included in this analysis. This paper reports
data from 78 participants: data from six interviews with those
with ID will be reported elsewhere.
Remembering recruitment to the GOLD study
Our participants reported that they came to participate in the
GOLD study because they wanted to find the cause of the ID in
their family. So how did they experience the recruitment
process? Many of those who had given blood or proxy
permission for their son/brother talked about how they had
been asked to participate. Like the respondent below, most had
been approached by a known healthcare professional as a
continuation of either their own, or a relative’s, clinical genetics
consultation.
I: And then how did you come to be recruited …
R1: Professor [geneticist], he suggested it, he said that they
couldn’t find any results, because they checked [son] for fragile X
and obviously the Downs bit ... but there was nothing in that …
which was good, all the results came back fine, but he said that
there was somewhere in Cambridge, and he explained about
[research nurse] and what she does, and would I be interested.
And I said yeah, I wouldn’t mind doing that, and then he just
explained well … if you don’t want it done it doesn’t mean we’re
going to cross you off our books and … and I said well no, that’s
fine, and then it was left for quite a while, and then I was written
to and I thought yeah, I’ll do this then. (GO_22_01 mother and
sister)
Some were contacted months/years after attending a clinic.
These individuals said they were pleased to receive the
invitation to participate ‘‘out of the blue’’ because they felt
that this was an indication that something was being done
about the situation in their family:
iThe consent form and information sheet for families participating in the research
study of the genetics causes of learning disability (GOLD) can be accessed at: http://
goldstudy.cimr.cam.ac.uk/consentforms.htm.
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blue. Can you talk me through what happened, you know, sort
of how you heard, what went on?
M: [research nurse] contacted us first to say she’d be interested in
doing blood tests.
I: Right, and that was the first you’d heard?
M: Yes, after Dr [paediatrician] sent off the letters. And we were
just delighted that some sort of investigation … because it’s too
bland to say there may be a genetic link, I wanted proof there
was a genetic link. (GO_15_01 mother, last contact with genetics
service 3–4 years previously at her instigation)
Several families had participated in previous genetic research
studies and therefore, had given blood samples before, some-
times many years ago. These families were also pleased to be
approached to take part in the GOLD study:
I: How did you get recruited to that (GOLD) can you remember?
R: Through Dr [geneticist seen 12 years previously], he phoned
me up and I thought I’d never hear from him again. So that was
quite a surprise.
I: So you had had blood samples taken when [son] was about
9 months and this was the next time since then? How did you
feel about being phoned up?
R: You know I was quite pleased really because it was results and
then even better when he said there was someone in Cambridge
who was interested in coming up to see us and finding out what
sort of help we could get—I thought it was really good because I
had really given up hope. (GO_10_01 mother and sister)
These three responses illustrate how the majority of
participants remembered the initial approach. Many could
name the clinician who had approached them because often s/
he was responsible for their routine care. A minority of our
participants could not recall who had made the initial approach
for the GOLD study.
Members of the extended family, who had not been to a
clinic, recalled how a relative had approached them with
information about the study and a request to participate:
I: So how did it come that you were all involved in this GOLD
Study of the blood samples, can you remember how all that came
about?
R1: Oh, [cousin] … most of this has come from [cousin].
I: That’s all come from [cousin]? Right, and can you talk me
through what happened, who told who what …
R1: Well I don’t know, [cousin’s mother] … there was talk of
something going on, but it didn’t actually come to anything. But
we said well, if there is anything going on, we’ll obviously be
involved. (GO_03_05 grandmother)
Thus, the data suggest that our participants were easily able
to recall the initial invitation to participate.
Knowing the goals, risks and benefits of the research
To be informed about research, participants need to know what
the research is about, what will happen to them, and what are
the potential harms and benefits.
3 The MREC-approved
information sheet for the GOLD study covered all these topics.
i
Potential study participants were informed that: faulty genes
sometimes cause learning disability; blood samples would be
taken; a result may take up to five years, but not all families
could expect to gain a result; and, where a result was found, it
would help provide answers to the questions ‘‘Why does our
child have learning disability?’’ and ‘‘Will our next child have
learning disability?’’ They were also told about issues of
confidentiality, about their right to decide to take part and
withdraw.
All the people we interviewed were aware that the aim of the
GOLD study was to look for causes of ID in families. Most
knew it was genetic research, and all had a realistic expectation
that the results, if any became available, were likely to take a
very long time in coming:
R: Oh well they sent me a letter about the genetics part of it and
said could she come down and take blood samples, and she came
down and she took blood samples and more or less said that there
was other families involved and it could take about five years.
(GO_05_01 mother and sister)
Although a few people thought a ‘‘diagnosis’’ would help
themselves, or other family members, to access care or benefits,
most knew the research was unlikely to help those currently
affected with ID, but perceived the research as potentially
helping people in the future.
... of course, I mean if it’s going to benefit people in years to
come. Like there’s no benefit for us apart from the knowledge
that… if they can find something out (GO_15_03 mother)
All but one knew that genetic research may lead to a test
which in turn could lead to more informed reproductive choices,
(the ID in this participant’s family was mild). This aspect of
research participation was very important to those of our
respondents who wanted to prevent future boys with ID being
born into their family:
R: Well the main reason we’ve taken part is… for my daughter
and my sister’s two daughters… So that perhaps they can be
screened before having any children (GO_O7_01 mother, sister
and aunt)
Potential risks included unrealistic expectations about what
might be achieved or how quickly and the potential for
disappointment if no results emerged. However, our study
participants appeared to understand these risks. Many talked
about the time lag between giving blood and gaining a result,
and the possibility that tangible results may not emerge from
the research:
M: … well, it’s a four year study I think, and … well I think they
would contact us certainly if they could find anything specific, if
they don’t, I’m not sure whether to expect to hear from them or
not. But it was very informative at the time of giving blood, the
person who came. (GO_03_03 mother)
Thus it would appear that many of those interviewed were
aware of the goals of the GOLD study and the potential risks
and benefits to their family and others. In this sense at least,
their consent can be regarded as informed. However, as the
following section demonstrates few could recall the details of
the consent process, such as signing a consent form.
Recalling formal aspects of the consent process
All participants of the GOLD study were given a five-part
consent form to sign along with the information sheet. The
form specified consent to take part, withdraw without notice,
access to medical records, a blood sample being taken and the
establishment of cell lines. These were signed by participants or
their proxies. However, many appeared unable to recall signing
the form:
R: I signed a form when I was with [researcher], but I can’t
remember what it was for. (GO_04_01 mother and grandmother)
I: Did you sign anything? Any consent forms, do you remember?
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gave a particularly good account of what the research was about)
This may be explained by three factors. First, participants
appeared to find the decision to participate in the study
uncontentious:
I: So was it at all difficult to decide to take part or was it
something you had to talk about among yourselves or …?
R1: No, no it wasn’t difficult was it, it was just something … I
think I made the decision to go, look into it yeah. (GO_18_04
mother and aunt)
I: Did you feel there was any sort of decision needed to be made
about whether or not you wanted to take part?
R: No, no question. Because unless we support you, how can you
support us? (GO_07_01 mother)
Secondly, they said that once they had given blood they had
rarely thought about the study beyond sometimes wondering if
there would be a result:
I: Is it something you think about?
R: Well yes, obviously you think about it from time to time, and
just wonder where it’s going, or is there ever going to be any
answers, that’s what I always think, is there going to be any. I’m
not saying it’s a waste of time, I’m just saying what’s at the end
of the road, is there anything there? (GO_06_01 mother and
grandmother)
And thirdly, as illustrated above, they had remembered the
telephone calls, letters and consultations where the GOLD
study had first been introduced as the point or time at which
they had agreed to take part. Thus the subsequent receipt of the
Patient Information Sheet (PIS) and signing the consent form
appeared less memorable.
Similarly, those recruited through relatives had little recollec-
tion of the formal consent procedures, such as receiving the PIS
or signing a consent form:
I: Did you have to sign a consent form before you gave blood,
were you given any written information?
R1: [long pause]
R2: No, I’d have seen it wouldn’t I.
R1: Well you weren’t there [husband], were you?
R2: No, but you’d have brought it back, if you’d had anything
given to you …
R1: I don’t … no, I don’t think so, no.
I: Right, so there was nothing …
R1: No, not that I can remember. (GO_03_ 05 & 08 grandparents
and cousin)
It was clear that some parents of affected boys had
expectations that their relatives would participate in the
GOLD study by providing blood samples. As the quotation
below illustrates, they felt their relatives had a duty to do this
even if those family obligations did not extend to helping with
practical care of people with ID:
… The rest of the family, I insisted that they have the blood test.
I don’t care whether they support me with the children or this or
that, but … I think they are duty bound to provide a blood
sample. And that’s all that’s expected of them. I don’t want any
more, just the blood samples. (GO_15_01 mother)
We do not know what this woman’s relatives would say
about their memory of consent nor to what extent they might
have felt coerced to participate. However, a number of
participants from other families told us that they had willingly
taken part in the GOLD study because they wanted to help
their family:
I: How were you told about the study? Did it come from the
doctors or from [daughter]?
R: It’s all come from [daughter].
I: It all came from her. And she roped you into—sticking your
arm out …
R: I don’t mind. It was really, she just said, oh well such-and-
such got in touch with me and they want your blood. And I said
all right. That’s more or less how it’s come about. But we’re quite
prepared to go along with it. (GO_06_01 mother and grand-
mother)
DISCUSSION
In this paper we have reported data describing participants’
recall of how they came to take part in a research study which
sought to determine the genetic basis of learning disabilities in
families (the GOLD study). They recalled being recruited to the
GOLD study by either a familiar clinician or members of the
GOLD team, and were reasonably well informed about the
goals, risks and benefits of the research. Recent legislation
2
requires explicit consent for participation in research that uses
human tissue samples, and there is a general presumption that
any consent to research will be documented.
5 Our study
suggests that although participants recalled agreeing to partici-
pate and receiving information about the research from their
clinician/study team or family members, the formal process of
giving signed consent was less memorable. Although we cannot
be sure that the written consent process had not helped to
reinforce the accuracy with which participants appeared to
recall the GOLD study, these observations do raise questions
about the role and purpose of written consent in research.
One explanation for our participants’ lack of recall of
providing written consent and receiving the patient information
leaflet may be that they did not perceive the procedures carried
out as part of the GOLD study as differing from the clinical care
they or their relatives had previously received. For these
families, normal clinical care would have included family
history taking, blood sampling and relatives being asked to give
information and blood samples, just as happened when they
became part of the GOLD study. Thus, because this process was
similar to what had previously happened participants may have
paid less attention to the formalised procedures for obtaining
their consent for research. Furthermore, because our partici-
pants had been unable to obtain a diagnosis for the ID in their
family via a clinical route, they may have perceived research
participation as a logical next step in their search for an answer.
Clinicians in this sub-specialty regularly invite their patients to
enter into research studies in order to identify disease-
predisposing genetic mutations. These observations support
Parker et al’s
17 views that the boundary between research and
clinical practice in rare genetic disorders is becoming increas-
ingly ambiguous, for both clinicians and patients. However, the
push from regulators has been to insist on a clear boundary
between research and clinical activity.
The data support the arguments that consenting in research
should be seen as a process rather than as a single event
71 8and
that the process should recognise the specific context of those
being asked to give consent. The process of consenting to take
part in the GOLD study took place for these families at a stage
when they had already embarked on a process of genetic
investigation. The point at which it slipped from being a purely
clinical activity into a research activity was not significant to
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were doing or were uninformed, merely that these families did
not see an important distinction between what was research
and what was not.
17 Clinical care evolved towards research and
families reported that they felt adequately informed along the
path. The challenge for researchers is to ensure that participants
continue to be informed and are adequately cared for through-
out the research and after it ends.
It must be noted that there are limitations to this study. The
families who took part in our study are a select group. They are
all participants in a molecular genetics study (the GOLD study)
and data about those who declined to participate are unavail-
able. Of those who participated and were invited to join this
additional family study, only 40% agreed. We know nothing
about those individuals who either declined our invitation, or
who were not invited by their relatives. Our families have a very
favourable view of research because they appear to perceive it as
their only route to getting a diagnosis which may help their
families in the future. The condition being investigated in the
GOLD study was ID and we cannot assume that those who
participate in genetic research for other types of disorder will
report similar experiences.
CONCLUSION
Research has become regulated in an effort to accommodate all
types of research in a single process. This has led to the
formalisation of consent procedures, such as providing compre-
hensive information leaflets and long and complex written
consent forms. These are seen as essential to protect people
from harm in drug trials or other risky interventions. However,
our data suggest that the current emphasis on signed consent
may be less relevant in some circumstances. In an exploratory
genetic study such as the GOLD study, our participants
indicated that written consent was not an issue because the
research was seen as a continuation of a process already started
in the clinic. Moreover, in most cases, the person inviting them
to participate was the clinician responsible for their care with
whom they had a trusting relationship.
9 We would always
endorse that consent to participate in research is necessary and
desirable. However, we believe that there could be more
flexibility in the consent procedures required by ethics
committees, such that they fit with the particular type of
research being undertaken. Clinical genetics practice now
includes documenting that people have agreed to genetic testing
and that they understand all possible consequences.
12 This
agreement should suffice for research activity which is a direct
continuation of clinical practice. However, this means that
when investigations do move into the research phase, clinicians
and clinician-researchers must ensure that they have discussed
the specific research fully and that high standards of clinical care
continue for their patients throughout the research period. This
may need to be addressed more explicitly than is done at present
through the system of annual and/or end of study reports
required by ethics committees.
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